Syndax Pharmaceuticals (SNDX) Change in Acquisitions & Divestments (2015 - 2026)

Syndax Pharmaceuticals' Change in Acquisitions & Divestments history runs 12 years deep, the most recent figure standing at $77.8 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 25.7% year-over-year to $77.8 million in Q1 2026; TTM through Mar 2026 was $459.1 million, a 22.77% increase from a year earlier, with the FY2025 full-year figure at $486.0 million, up 44.1% from the prior year.
• Change in Acquisitions & Divestments fell to $77.8 million in Q1 2026 per SNDX's latest filing, from $144.8 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $154.9 million in Q2 2023 and bottomed at $50.4 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $103.0 million (2025), against an average of $99.0 million.
• Across the five-year window, Change in Acquisitions & Divestments surged 149.45% in 2022 and tumbled 60.14% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $113.2 million in 2022, then fell by 0.22% to $113.0 million in 2023, then declined by 5.01% to $107.3 million in 2024, then surged by 34.85% to $144.8 million in 2025, then slumped by 46.27% to $77.8 million in 2026.
• Per Business Quant, the three latest SNDX Change in Acquisitions & Divestments figures stand at $77.8 million (Q1 2026), $144.8 million (Q4 2025), and $103.0 million (Q3 2025).